Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 20/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3433815 | 0.92 | PTGER1 (0.64) | PTGER1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3434489 | 0.91 | PTGER1 (0.61) | PTGER1 | |
| SCHEMBL3433669 | 0.90 | PTGER1 (0.62) | PTGER1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3435608 | 0.86 | PTGER1 (0.61) | PTGER1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL255383 | 0.85 | PTGER1 (0.56) | PTGER1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL255384 | 0.85 | PTGER1 (0.56) | PTGER1 | |
| SCHEMBL14956245 | 0.85 | PTGER1 (0.59) | PTGER1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14956294 | 0.84 | PTGER1 (0.59) | PTGER1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL252051 | 0.83 | PTGER1 (0.55) | PTGER1CYP2C9 | |
| SCHEMBL14956268 | 0.83 | PTGER1 (0.61) | PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2945932-B1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2018-11-21 | — | — | EP | claimed |
| EP-2588459-B1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2017-03-01 | — | — | EP | disclosed |